{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"technology_type":["Illumina HiSeq 2500, ILLUMINA"],"study_type":["Other"],"full_dataset_link":["https://ega-archive.org/studies/EGAS00001002894"],"host":["EGA"],"description":["EGA study EGAS00001002894"],"dataset_title":["Total RNA sequencing of 32 chronic lymphocytic leukemia (CLL) patients"],"repository":["EGA"],"category":["restricted"],"name_synonyms":["Lymphoplasmacytoid Lymphomas, CLL Lymphoplasmacytoid Lymphomas, CLL, Chronic B-Cell Leukemia, Chronic B-Cell, Lymphocytic Leukemia, Multicenter Studies., B-Lymphocytic Leukemias, chronic LYMPHOCYTIC, Chronic B-Lymphocytic, B-Cell, Visible Light, Lymphatic Leukemia, B-cell chronic lymphocytic leukaemia, Ly113, B Cell, Small, B-cell chronic lymphoid leukemia, Chronic B-Cell Leukemias, Well-Differentiated Lymphocytic, Lymphoplasmacytoid Lymphoma, Well Differentiated, Chronic Lymphocytic Leukemias, Lymphomas, chronic lymphatic, Low-Grade, Lymphocytic, Leukemia, B-cell chronic lymphocytic leukemia, Malignancy, Small-Cell Lymphomas, CLL Lymphoplasmacytoid Lymphoma, Plasmacytoid, Small Lymphocytic Lymphoma, Well-Differentiated Lymphocytic Lymphoma, Visible, Small-Cell Lymphoma, B-Lymphocytic Leukemia, Diffuse, Lymphoblastic Leukemias, TNFSF14, ch, Chronic Lymphatic Leukemias, Disrupted In B Cell Malignancy, Chronic, Diffuse Well Differentiated Lymphocytic Lymphoma, Malignancies, TR2, Chronic B-Lymphocytic Leukemias, chronic lymphatic leukaemia, Chronic Lymphocytic, Diffuse Well-Differentiated Lymphocytic Lymphoma, Low Grade, leukemia, B-Cell Chronic Lymphocytic Leukemia, Radiation, UNQ391/PRO726, B Cell Malignancy, Small Cell, Chronic Lymphocytic Leukemia, Chronic B-Lymphocytic Leukemia, lymphoplasmacytic leukaemia, B-Cell Malignancy, Light, Low-Grade B-Cell Malignancies, Chronic Lymphoblastic Leukemia, CD258, lymphoplasmacytic leukemia, Leukemias, chronic, results, B-Cell Leukemia, Well-Differentiated, LIGHT, Chronic Lymphatic, Small Cell Lymphoma, Lymphocytic Leukemias, B-Cell Malignancies, B Lymphocytic Leukemia, B Cell Chronic Lymphocytic Leukemia, chronic lymphatic leukemia, B Cell Leukemia, lymphocytic, Low-Grade B-Cell, Visible Radiations, Radiations, Lymphoblastic Leukemia, Chronic Lymphatic Leukemia, small lymphocytic lymphoma, Visible Radiation, Lymphatic Leukemias, HVEML, Lymphocytic Lymphomas, Well-Differentiated Lymphocytic Lymphomas, HVEM-L, B-Cell Leukemias, Photoradiation, Disrupted In B-Cell Malignancy, Lymphoblastic, Chronic Lymphoblastic, Small Lymphocytic, Chronic Lymphoblastic Leukemias, LTg, Low-Grade B-Cell Malignancy, Small-Cell, Photoradiations, Lymphocytic Lymphoma, Lymphoplasmacytoid, CLL Lymphoplasmacytoid, Lymphoma, chronic lymphocytic leukaemia, Small Lymphocytic Lymphomas"],"description_synonyms":["Experimental Designs, IPP2A2, Research Technique, Materials, Problem Formulations, Adjustments, RNA Sequence Determination, determination, Sequence Determination, Globulin, RNA Sequence, Design, Error Sources, Immune Globulin, myc-B, DmelCG10798, Visible Light, MYC, Myc, Technic, Long Term, B430311C09Rik, 5730420M11Rik, dmTAF[[II]]230, Relative, Techniques, c-MYC, c-Myc, EG:BACN5I9.1, Method, BCR, ARC, CG40494, Analysis, Polymerase Chain, myc, Effect, chronic lymphatic, Experimental Design, BCR1, imprinted and ancient gene protein, Group, treatment, SET, c-myc, Prognoses, TFIID TAF250, B-cell chronic lymphocytic leukemia, Analyses, cel, Determination, TAF-I, dm/dMyc, Multivariate Analyses, Matched Group, Designs, Matched, Inverse Polymerase Chain Reaction, Groups, protein synthesis initiation, experimental design, Sequence Determinations, free, adult chronic leukaemia, DmelCG4299, AI853148, IGAAD, set, geographical area, TNFSF14, ch, high frequency, Immune, DmelCG10574, Reporting, Reaction, disease management, Research Techniques, Therapies, adult chronic leukemia, chronic lymphatic leukaemia, Long-Term Effects, single organism signaling, Data Reporting, Therapy, phapii, dTAF[[II]]230, Anchored Polymerase Chain Reaction, Radiation, biopolymerization, dmyc1, AU016757, Research Technic, UNQ391/PRO726, Research Methodology, TAF200, Longterm Effect, Research Proposals, StF-IT-1, Light, TAFII-250, TAF250/230, lymphoplasmacytic leukemia, results, Research Proposal, Determinations, D22S662, TAFII250, Experimental, LIGHT, Dm, Relative Risks, NOP, Genetic Materials, Technics, chronic lymphatic leukemia, Problem Formulation, lymphocytic, mMyc, Problem, Genetic Material, AI561783, PCR, Visible Radiations, l(1)G0354, Visible Radiation, Factors, positional polypeptide feature, HVEML, HLA-DR-associated protein II, translation initiation, death rate, Risk, Nested Polymerase Chain Reaction, DI-2, Prognostic, I-2Dm, l(1)G0359, CG7937., INSDC_feature:gene, CG4299, d-myc, CG17603, TAF[[II]], CG17960, Treatments, D-Myc, polymerase chain reaction, Myc2, Formulations, I-2PP1, immunoglobulin, Niard, TAF-IBETA, myc2, Taf250, Patient, Material, SR3-5, Cistron, chronic lymphocytic leukaemia, Globulins, TAF-Ibeta, dMyc1, E430016J11Rik, MRTL, i2pp2a, Data Adjustments, TAF230, Prognostic Factor, Dmel_CG00000, CG10798, CLL, Cll, d230, Immunoglobulin, dm/myc, region or site annotation, Effects, l(1)G0139, 5133400C09Rik, Matched Groups, number, chronic LYMPHOCYTIC, Gene, high weight, dTAFII250, Prognostic Factors, Scoring Method, Polymerase Chain Reactions, Inverse, EfW1, Ximpact, presence, B-cell chronic lymphocytic leukaemia, dMyc, dMYC, PHAPII, Ly113, cll, antibody, CML, Adjustment, Inverse PCR, anon-WO03040301.171, CG17617, MYCC, dmTAF1, Taf230, Scoring Methods, B-cell chronic lymphoid leukemia, Sources, heavy, c-myc II, rhoGAP1A, Nop30, bHLHe57, Technique, Sanger sequencing, TAF250, DmelCG40494, positional, Taf200, Methodology, dTAF[[II]]250, Genetic, Scoring, Research, Longterm, cell, Proposals, D22S11, ipp2a2, Dmyc, DMYc, 2pp2a, Taf1p, PHL, Visible, EG:23E12.5, Long-Term, EG:23E12.2, Sequencing, CG10574, Research Strategy, dye terminator sequencing, Ect5, biopolymerisation, BHLHE39, dTAF250, 2PP2A, Nird, RNCMYC, RNA Sequence Analyses, taf-ibeta, time of survival, Clients, Error Source, dSET, dSet, RNA Sequencing, Long-Term Effect, TR2, Anchored PCR, Strategies, TAF, bHLHe39, dmyc, CG7937, Sequence Analyses, leukemia, ALL, RNA, TAF[[II]]250, RNA Sequence Determinations, Chronic Lymphocytic Leukemia, igaad, lymphoplasmacytic leukaemia, 311, l(3)84Ab, Formulation, Factor, BG:DS00004.13, Cistrons, CD258, Immune Globulins, Client, chronic, Cell, impact-a, Multivariate, group, dTAF230, Research Strategies, count in organism, survival, 93Bal, I-2PP2A, p230, CG40453, Long Term Effects, Dm I-2, chemical analysis, I2PP2A, sequence, TAF[[II]]250/230, TFIID, imprinted and ancient gene protein homolog, IMPACT, Proposal, Methods, Relative Risk, opsonin activity, Radiations, Taf[[II]]250, small lymphocytic lymphoma, Anchored, c15, TAF[[II]]230, Reactions, Nested, frequent, ensemble, HVEM-L, Source, DmelCG7937, Risks, Photoradiation, Research Designs, TAF[II]250, Research Technics, primary structure of sequence macromolecule, LTg, Longterm Effects, Data Adjustment, dSET/TAF-Ibeta, Hox11-311, 2610030F17Rik, DmelCG17603, Photoradiations, signalling process, Error, Therapeutic, Data, RNA Sequence Analysis, B cell receptor activity, Nested PCR, Treatment, ribosome biogenesis and assembly, assay, mKIAA3017, Strategy, AA407739, RWDD5, TAF1"],"additional_accession":[]},"is_claimable":false,"name":"The light chain IgLV3-21 defines a new poor prognostic subgroup in Chronic Lymphocytic Leukemia: results from a multicenter study","description":"Purpose: Unmutated (UM) immunoglobulin heavy chain region (IgHV) status or IgHV3-21 gene usage is associated with poor prognosis in chronic lymphocytic leukemia (CLL). Interestingly, IgHV3-21 is often co-expressed with light chain IgLV3-21 which is potentially able to trigger cell-autonomous BCR-mediated signaling. However this light chain has never been characterized independently of the heavy chain IgHV3-21.Experimental Design: we performed total RNA sequencing to characterize IgLV3-21 patients (n=32) and investigated IgLV3-21 prognostic impact in terms of treatment-free (TFS) and overall (OS) survival in 3 other independent cohorts for a total of 813 patients where IgLV3-21 presence was tested by real-time PCR and confirmed by Sanger sequencing.Results: Using total RNA sequencing to characterize 32 patients with high-risk CLL, we found a high frequency (28%) of IgLV3-21 rearrangements. Gene set enrichment analysis revealed that these patients present higher expression of genes responsible for ribosome biogenesis and translation initiation (P<0.0001) and MYC target genes (P=0.0003). Patients with IgLV3-21 rearrangements displayed a significantly shorter TFS and OS (P<0.05), in particular in IgHV mutated patients. In each of the 3 independent validation cohorts (n=813), we showed that IgLV3-21 rearrangements -similar to UM IgHV status- conferred poor prognosis compared to mutated IgHV (P<0.0001). Importantly, we confirmed in multivariate analysis that this was independent of IgHV mutational status or subset #2 stereotyped receptor (P<0.0001). Conclusions: We therefore demonstrate for the first time that a light chain can impact on CLL prognosis and that IgLV3-21 light chain usage defines a new poor prognostic subgroup in CLL.","dates":{"updated":"2020-07-16 15:33:08"},"accession":"EGAS00001002894","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAD00001004047","EGAC00001000866"]}}